{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:37:01Z","timestamp":1789504621982,"version":"build-2803163510"},"reference-count":152,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.trre.2021.100655","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T15:17:15Z","timestamp":1632496635000},"page":"100655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients"],"prefix":"10.1016","volume":"36","author":[{"given":"Helio","family":"Tedesco-Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faouzi","family":"Saliba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus J.","family":"Barten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Potena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apurva","family":"Gawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2021.100655_bb0005","series-title":"Kidney transplantation - principles and practice","first-page":"9","article-title":"2 - the immunology of transplantation","author":"Castro-Dopico","year":"2019"},{"key":"10.1016\/j.trre.2021.100655_bb0010","doi-asserted-by":"crossref","first-page":"i29","DOI":"10.1093\/bja\/aer384","article-title":"Organ transplantation: historical perspective and current practice","volume":"108","author":"Watson","year":"2012","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.trre.2021.100655_bb0015","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/ajkd.2001.28921","article-title":"Evolution of immunosuppression and continued importance of acute rejection in renal transplantation","volume":"38","author":"Chan","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2021.100655_bb0020","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2021.100655_bb0025","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/aor.13551","article-title":"Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity","volume":"44","author":"Bentata","year":"2020","journal-title":"Artif Organs"},{"key":"10.1016\/j.trre.2021.100655_bb0030","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1097\/TP.0000000000001243","article-title":"Calcineurin inhibitor nephrotoxicity through the Lens of longitudinal histology: comparison of Cyclosporine and Tacrolimus eras","volume":"100","author":"Nankivell","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0035","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1432-2277.2008.00780.x","article-title":"Neurologic complications after solid organ transplantation","volume":"22","author":"Senzolo","year":"2009","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2021.100655_bb0040","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1399-0012.2009.00957.x","article-title":"A single-staggered dose of calcineurin inhibitor may be associated with neurotoxicity and nephrotoxicity immediately after liver transplantation","volume":"23","author":"Urbani","year":"2009","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0045","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ecl.2007.07.003","article-title":"Immunosuppressive agents: effects on glucose and lipid metabolism","volume":"36","author":"Subramanian","year":"2007","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.trre.2021.100655_bb0050","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ackd.2019.08.006","article-title":"The many faces of calcineurin inhibitor toxicity-what the FK?","volume":"27","author":"Farouk","year":"2020","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.trre.2021.100655_bb0055","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.transproceed.2010.07.006","article-title":"Clinical insights for cancer outcomes in renal transplant patients","volume":"42","author":"Alberu","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2021.100655_bb0060","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/TP.0b013e3182230900","article-title":"Everolimus and long-term outcomes in renal transplantation","volume":"92","author":"Campistol","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0065","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.26859","article-title":"Gender differences in cancer risk after kidney transplantation","volume":"10","author":"Buxeda","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.trre.2021.100655_bb0070","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2021.100655_bb0075","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.semnephrol.2007.03.010","article-title":"Renal disease in recipients of nonrenal solid organ transplantation","volume":"27","author":"Ojo","year":"2007","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.trre.2021.100655_bb0080","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00007890-199707150-00008","article-title":"SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo","volume":"64","author":"Schuler","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0085","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nri3198","article-title":"Regulation and function of mTOR signalling in T cell fate decisions","volume":"12","author":"Chi","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.trre.2021.100655_bb0090","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/S0041-1345(98)00587-9","article-title":"Chemical modification of rapamycin: the discovery of SDZ RAD","volume":"30","author":"Sedrani","year":"1998","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2021.100655_bb0095","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1399-0012.2005.00326.x","article-title":"Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data","volume":"19","author":"Lorber","year":"2005","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1432-2277.2006.00414.x","article-title":"12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients","volume":"20","author":"Tedesco-Silva","year":"2007","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2021.100655_bb0105","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1097\/01.TP.0000141094.34903.54","article-title":"Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients","volume":"78","author":"Vitko","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0110","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients","volume":"349","author":"Eisen","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2021.100655_bb0115","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2012.04212.x","article-title":"Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial","volume":"12","author":"De Simone","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0120","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/TP.0b013e3181af1df6","article-title":"Homan van der Heide JJ et al. minimization of maintenance immunosuppression early after renal transplantation: an interim analysis","volume":"88","author":"Bemelman","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0125","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1399-0012.2008.00795.x","article-title":"Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study","volume":"22","author":"Holdaas","year":"2008","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0130","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1097\/01.TP.0000140486.97461.49","article-title":"Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study","volume":"78","author":"Nashan","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0135","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients","volume":"10","author":"Tedesco Silva","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0140","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13157","article-title":"Renal protection strategies after heart transplantation","volume":"32","author":"Reichart","year":"2018","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0145","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/bcp.12289","article-title":"Impact of the reduction of calcineurin inhibitors on renal function in heart transplant patients: a systematic review and meta-analysis","volume":"78","author":"Cornu","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.trre.2021.100655_bb0150","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/TP.0b013e3181cbac2d","article-title":"Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial","volume":"89","author":"Gullestad","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0155","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/01.tp.0000235527.81917.fe","article-title":"Cardiovascular complications after renal transplantation and their prevention","volume":"82","author":"Ojo","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0160","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.transproceed.2008.10.015","article-title":"Minimizing the risk of posttransplant malignancy","volume":"40","author":"Campistol","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2021.100655_bb0165","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","article-title":"Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial","volume":"87","author":"Schena","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0170","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1111\/j.1600-6143.2005.01063.x","article-title":"Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients","volume":"5","author":"Vitko","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0175","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.trre.2021.100655_bb0180","first-page":"97","article-title":"Everolimus in kidney transplantation","volume":"3","author":"Cooper","year":"2011","journal-title":"Transplant Res Risk Manag"},{"key":"10.1016\/j.trre.2021.100655_bb0185","doi-asserted-by":"crossref","first-page":"495S","DOI":"10.1016\/j.transproceed.2004.01.015","article-title":"The evolving experience using everolimus in clinical transplantation","volume":"36","author":"Formica","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2021.100655_bb0190","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0090-9556(24)15260-9","article-title":"Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats","volume":"27","author":"Crowe","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.trre.2021.100655_bb0195","first-page":"293","article-title":"The role of mTOR inhibitors in solid organ transplantation","author":"Mc Kenna","year":"2016","journal-title":"Mol Med mTOR"},{"key":"10.1016\/j.trre.2021.100655_bb0200","doi-asserted-by":"crossref","first-page":"E401","DOI":"10.1111\/j.1399-0012.2011.01446.x","article-title":"Conversion from sirolimus to everolimus in kidney transplant recipients receiving a calcineurin-free regimen","volume":"25","author":"Carvalho","year":"2011","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0205","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/FTD.0000000000000260","article-title":"Therapeutic drug monitoring of Everolimus: a consensus report","volume":"38","author":"Shipkova","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.trre.2021.100655_bb0210","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1592\/phco.22.3.154.33542","article-title":"Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants","volume":"22","author":"Kovarik","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.trre.2021.100655_bb0215","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mcp.2001.112969","article-title":"Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine","volume":"69","author":"Kovarik","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.trre.2021.100655_bb0220","author":"Certican\u00ae"},{"key":"10.1016\/j.trre.2021.100655_bb0225","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/0091270002042001011","article-title":"Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction","volume":"42","author":"Kovarik","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.trre.2021.100655_bb0230","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/j.transproceed.2006.10.092","article-title":"Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus","volume":"38","author":"Kovarik","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2021.100655_bb0235","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1097\/TP.0b013e3181ccd7f2","article-title":"Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial","volume":"89","author":"Pascual","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0240","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000164352.65613.24","article-title":"Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study","volume":"80","author":"Lorber","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0245","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2047-1440-2-14","article-title":"Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results","volume":"2","author":"Takahashi","year":"2013","journal-title":"Transplant Res"},{"key":"10.1016\/j.trre.2021.100655_bb0250","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1016\/j.transproceed.2011.10.032","article-title":"De novo use of everolimus with elimination or minimization of cyclosporine in renal transplant recipients","volume":"43","author":"Novoa","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2021.100655_bb0255","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/TP.0b013e318166927b","article-title":"Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness","volume":"85","author":"Chan","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0260","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1432-2277.2012.01465.x","article-title":"Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation","volume":"25","author":"Langer","year":"2012","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2021.100655_bb0265","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/ajt.14090","article-title":"Efficacy and safety of everolimus plus low-dose tacrolimus versus mycophenolate mofetil plus standard-dose tacrolimus in de novo renal transplant recipients: 12-month data","volume":"17","author":"Qazi","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0270","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1111\/ajt.14215","article-title":"Association of clinical events with everolimus exposure in kidney transplant patients receiving low doses of Tacrolimus","volume":"17","author":"Shihab","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0275","first-page":"45","article-title":"TRANSFORM: a novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation","volume":"6","author":"Pascual","year":"2014","journal-title":"J Clin Trials"},{"key":"10.1016\/j.trre.2021.100655_bb0280","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2019.01.041","article-title":"An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients","volume":"96","author":"Sommerer","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2021.100655_bb0285","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1681\/ASN.2018010009","article-title":"Everolimus with reduced calcineurin inhibitor exposure in renal transplantation","volume":"29","author":"Pascual","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2021.100655_bb0290","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/ajt.15480","article-title":"Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study","volume":"19","author":"Berger","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0295","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1097\/TP.0000000000003021","article-title":"Use of de novo mTOR inhibitors in hypersensitized kidney transplant recipients: experience from clinical practice","volume":"104","author":"Cucchiari","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0300","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0b013e318224c12d","article-title":"Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study","volume":"92","author":"Holdaas","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0305","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","article-title":"Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial","volume":"377","author":"Budde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2021.100655_bb0310","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ajt.12952","article-title":"Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study","volume":"15","author":"Budde","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0315","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/tri.12437","article-title":"Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation","volume":"28","author":"Mjornstedt","year":"2015","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2021.100655_bb0320","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/ajt.14186","article-title":"Early conversion from calcineurin inhibitor- to everolimus-based therapy following kidney transplantation: results of the randomized ELEVATE trial","volume":"17","author":"de Fijter","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0325","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/ndt\/gfx075","article-title":"Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from month 3: a multicentre, randomized trial","volume":"32","author":"Budde","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0330","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1111\/j.1600-6143.2012.04162.x","article-title":"Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation","volume":"12","author":"Mjornstedt","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0335","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1600-6143.2011.03961.x","article-title":"Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation","volume":"12","author":"Liefeldt","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0340","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1111\/j.1600-6143.2012.04159.x","article-title":"Does everolimus increase donor-specific HLA antibodies in kidney transplant recipients?","volume":"12","author":"Pascual","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0345","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.intimp.2016.07.019","article-title":"5-year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: retrospective single center assessment","volume":"39","author":"Hiramitsu","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.trre.2021.100655_bb0350","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/TP.0b013e3182848e03","article-title":"Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation","volume":"95","author":"Cibrik","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0355","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1600-6143.2012.03994.x","article-title":"Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study","volume":"12","author":"Budde","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0360","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/ajt.13132","article-title":"Fibrosis progression according to epithelial-mesenchymal transition profile: a randomized trial of everolimus versus CsA","volume":"15","author":"Rostaing","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0365","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/ajt.14048","article-title":"Early conversion to prednisolone\/everolimus as an alternative weaning regimen associates with beneficial renal transplant histology and function: the randomized-controlled MECANO trial","volume":"17","author":"Bemelman","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0370","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/lt.20707","article-title":"Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results","volume":"12","author":"Levy","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2021.100655_bb0375","first-page":"1455","article-title":"Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: follow-up results from a randomized","volume":"99","author":"Fischer","year":"2015","journal-title":"Multicenter Study Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0380","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/ajt.14623","article-title":"Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study","volume":"18","author":"Jeng","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0385","article-title":"Efficacy and safety of everolimus with reduced tacrolimus in liver transplant recipients: 24-month results from the pooled analysis of two randomized controlled trials","author":"Lee","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0390","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/ajt.12615","article-title":"Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation","volume":"14","author":"Sterneck","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0395","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/ctr.12744","article-title":"Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study","volume":"30","author":"Sterneck","year":"2016","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0400","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/lt.21827","article-title":"Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial","volume":"15","author":"De Simone","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2021.100655_bb0405","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/ajt.14212","article-title":"Efficacy and safety of everolimus and mycophenolic acid with early tacrolimus withdrawal after liver transplantation: a multicenter randomized trial","volume":"17","author":"Saliba","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0410","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1002\/lt.25664","article-title":"Early switch from tacrolimus to everolimus after liver transplantation: outcomes at 2 years","volume":"25","author":"Saliba","year":"2019","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2021.100655_bb0415","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/ajt.12280","article-title":"Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study","volume":"13","author":"Saliba","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0420","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/01.tp.0000542566.18089.a5","article-title":"Renal function outcomes with Everolimus plus reduced-exposure tacrolimus in de novo living donor liver transplantation: 24-month results from the H2307 study","volume":"102","author":"Suh","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0425","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/j.1600-6143.2012.04049.x","article-title":"A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation--PROTECT","volume":"12","author":"Fischer","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0430","doi-asserted-by":"crossref","DOI":"10.1002\/lt.25879","article-title":"Time to conversion to an everolimus-based regimen: renal outcomes in liver transplant recipients from the EVEROLIVER registry","author":"Saliba","year":"2020","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2021.100655_bb0435","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/ajt.12181","article-title":"Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial","volume":"13","author":"Eisen","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0440","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/TP.0b013e3181aacd22","article-title":"Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients","volume":"88","author":"Lehmkuhl","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0445","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/tri.12783","article-title":"Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial","volume":"29","author":"Gullestad","year":"2016","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2021.100655_bb0450","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.15361","article-title":"Comparing everolimus-based immunosuppression with reduction or withdrawal of calcineurin inhibitor reduction from six months after heart transplantation: the randomized MANDELA study","author":"Barten","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0455","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1111\/ajt.12809","article-title":"Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial","volume":"14","author":"Andreassen","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0460","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/TP.0000000000002702","article-title":"Everolimus initiation with early calcineurin inhibitor withdrawal in de novo heart transplant recipients: long-term follow-up from the randomized SCHEDULE study","volume":"104","author":"Gustafsson","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0465","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/TP.0b013e31822057f1","article-title":"Effect of everolimus introduction on cardiac allograft vasculopathy\u2013results of a randomized, multicenter trial","volume":"92","author":"Arora","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0470","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/ajt.12208","article-title":"Differential effect of everolimus on progression of early and late cardiac allograft vasculopathy in current clinical practice","volume":"13","author":"Masetti","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0475","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1600-6143.2005.01134.x","article-title":"Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial","volume":"6","author":"Snell","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0480","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.healun.2014.06.001","article-title":"Three-year results of an investigator-driven multicenter, international, randomized open-label de novo trial to prevent BOS after lung transplantation","volume":"34","author":"Glanville","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0485","first-page":"3171","article-title":"Everolimus versus mycophenolate mofetil de novo after lung transplantation: a prospective, randomized","volume":"16","author":"Strueber","year":"2016","journal-title":"Open-Label Trial Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0490","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1111\/ajt.15251","article-title":"A randomized trial of everolimus-based quadruple therapy vs standard triple therapy early after lung transplantation","volume":"19","author":"Gottlieb","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0495","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/ctr.12418","article-title":"Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors","volume":"28","author":"Perbos","year":"2014","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0500","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/TP.0b013e3181c42b95","article-title":"Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study","volume":"89","author":"Potena","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0505","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.healun.2012.01.002","article-title":"Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study","volume":"31","author":"Potena","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0510","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.healun.2011.12.010","article-title":"Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate","volume":"31","author":"Arora","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0515","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/ajt.13588","article-title":"Everolimus initiation with early calcineurin inhibitor withdrawal in de novo heart transplant recipients: three-year results from the randomized SCHEDULE study","volume":"16","author":"Andreassen","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0520","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/01.qco.0000136933.67920.dd","article-title":"Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients","volume":"17","author":"Pereyra","year":"2004","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.trre.2021.100655_bb0525","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1056\/NEJMra064928","article-title":"Infection in solid-organ transplant recipients","volume":"357","author":"Fishman","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2021.100655_bb0530","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/tid.12007","article-title":"Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation","volume":"15","author":"Kobashigawa","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2021.100655_bb0535","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/tri.13478","article-title":"Prospective randomized study comparing everolimus and mycophenolate sodium in de novo kidney transplant recipients from expanded criteria deceased donor","volume":"32","author":"Ferreira","year":"2019","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2021.100655_bb0540","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000002626","article-title":"Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: an analysis from the randomized TRANSFORM study","volume":"103","author":"Tedesco-Silva","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0545","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/eji.202048855","article-title":"Effect of everolimus-based drug regimens on CMV-specific T-cell functionality after renal transplantation: 12-month ATHENA subcohort-study results","volume":"51","author":"Hauser","year":"2021","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.trre.2021.100655_bb0550","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/TP.0b013e318197c17d","article-title":"The decade of polyomavirus BK-associated nephropathy: state of affairs","volume":"87","author":"Ramos","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0555","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.2215\/CJN.02900707","article-title":"Viral infection after renal transplantation: surveillance and management","volume":"3","author":"Weikert","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2021.100655_bb0560","article-title":"Everolimus for BKV nephropathy in kidney transplant recipients: a prospective, controlled study","author":"Bussalino","year":"2020","journal-title":"J Nephrol"},{"key":"10.1016\/j.trre.2021.100655_bb0565","doi-asserted-by":"crossref","first-page":"310","DOI":"10.12659\/AOT.908429","article-title":"BK virus: a cause for concern in thoracic transplantation?","volume":"23","author":"Barten","year":"2018","journal-title":"Ann Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0570","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/TP.0000000000002147","article-title":"International liver transplantation society consensus statement on immunosuppression in liver transplant recipients","volume":"102","author":"Charlton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0575","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11892-009-0047-0","article-title":"Dyslipidemia following kidney transplantation: diagnosis and treatment","volume":"9","author":"Badiou","year":"2009","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.trre.2021.100655_bb0580","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/TRRM.S12217","article-title":"Impact of everolimus: update on immunosuppressive therapy strategies and patient outcomes after renal transplantation","volume":"3","author":"Tedesco-Silva","year":"2011","journal-title":"Transplant Res Risk Manag"},{"key":"10.1016\/j.trre.2021.100655_bb0585","doi-asserted-by":"crossref","first-page":"iii9","DOI":"10.1093\/ndt\/gfl295","article-title":"Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation","volume":"21","author":"Eisen","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0590","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/tri.12862","article-title":"Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation","volume":"29","author":"Cruzado","year":"2016","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2021.100655_bb0595","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1111\/tri.13322","article-title":"Homan van der Heide JJ, de Fijter HW et al. long-term cardiovascular outcome of renal transplant recipients after early conversion to everolimus compared to calcineurin inhibition: results from the randomized controlled MECANO trial","volume":"31","author":"van Dijk","year":"2018","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2021.100655_bb0600","doi-asserted-by":"crossref","first-page":"751","DOI":"10.12659\/AOT.911030","article-title":"Association between renal dysfunction and major adverse cardiac events after liver transplantation: evidence from an international randomized trial of everolimus-based immunosuppression","volume":"23","author":"Saliba","year":"2018","journal-title":"Ann Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0605","doi-asserted-by":"crossref","first-page":"F418","DOI":"10.1152\/ajprenal.90319.2008","article-title":"mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes","volume":"296","author":"Vollenbr\u00f6ker","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.trre.2021.100655_bb0610","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ctr.12045","article-title":"Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine","volume":"27","author":"Shihab","year":"2013","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0615","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1600-6143.2009.02973.x","article-title":"The incidence of cancer in a population-based cohort of Canadian heart transplant recipients","volume":"10","author":"Jiang","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0620","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.bpobgyn.2014.08.007","article-title":"Epidemiology of de novo malignancies after solid-organ transplantation: immunosuppression, infection and other risk factors","volume":"28","author":"Piselli","year":"2014","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.trre.2021.100655_bb0625","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1053\/j.seminoncol.2014.12.029","article-title":"The epidemiology of cancers in human immunodeficiency virus infection and after organ transplantation","volume":"42","author":"Grulich","year":"2015","journal-title":"Semin Oncol"},{"key":"10.1016\/j.trre.2021.100655_bb0630","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1093\/ndt\/gfm087","article-title":"Malignancy in renal transplantation: opportunities with proliferation signal inhibitors","volume":"22","author":"Chapman","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0635","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jacc.2017.10.077","article-title":"Temporal trends of de novo malignancy development after heart transplantation","volume":"71","author":"Youn","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.trre.2021.100655_bb0640","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1540-8191.2009.00858.x","article-title":"Malignancy after heart transplantation: analysis of 24-year experience at a single center","volume":"24","author":"Yagdi","year":"2009","journal-title":"J Card Surg"},{"key":"10.1016\/j.trre.2021.100655_bb0645","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/TP.0000000000000563","article-title":"Pretransplant malignancy as a risk factor for posttransplant malignancy after heart transplantation","volume":"99","author":"Yoosabai","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0650","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1111\/j.1600-6143.2007.01908.x","article-title":"Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients","volume":"7","author":"Webster","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0655","doi-asserted-by":"crossref","first-page":"7089482","DOI":"10.1155\/2019\/7089482","article-title":"Risk factors for developing nonmelanoma skin cancer after lung transplantation","volume":"2019","author":"Grager","year":"2019","journal-title":"J Skin Cancer"},{"key":"10.1016\/j.trre.2021.100655_bb0660","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4254\/wjh.v11.i3.261","article-title":"Hepatocellular carcinoma recurrence after liver transplantation: risk factors, screening and clinical presentation","volume":"11","author":"Filgueira","year":"2019","journal-title":"World J Hepatol"},{"key":"10.1016\/j.trre.2021.100655_bb0665","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/tri.13358","article-title":"2018 annual report of the European liver transplant registry (ELTR) - 50-year evolution of liver transplantation","volume":"31","author":"Adam","year":"2018","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2021.100655_bb0670","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13737-014-0022-4","article-title":"Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer?","volume":"4","author":"Geissler","year":"2015","journal-title":"Transplant Res"},{"key":"10.1016\/j.trre.2021.100655_bb0675","first-page":"93","article-title":"Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy","volume":"9","author":"Rivinius","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.trre.2021.100655_bb0680","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194975","article-title":"Effects of mTOR-is on malignancy and survival following renal transplantation: a systematic review and meta-analysis of randomized trials with a minimum follow-up of 24 months","volume":"13","author":"Wolf","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.trre.2021.100655_bb0685","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1111\/ajt.14948","article-title":"De novo or early conversion to everolimus and long-term cancer outcomes in kidney transplant recipients: a trial-based linkage study","volume":"18","author":"Ying","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0690","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.kint.2016.11.008","article-title":"The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine","volume":"91","author":"Lim","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2021.100655_bb0695","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/TP.0000000000002851","volume":"104","author":"Manzia","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0700","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0003-4975(01)02824-7","article-title":"Sternal wound infection after heart transplantation: incidence and results with aggressive surgical treatment","volume":"72","author":"Carrier","year":"2001","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.trre.2021.100655_bb0705","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/TP.0b013e3182279133","article-title":"Impact of de novo everolimus-based immunosuppression on incisional complications in heart transplantation","volume":"92","author":"Zuckermann","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0710","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijcard.2016.02.075","article-title":"Wound complications and surgical events in de novo heart transplant patients treated with everolimus: Post-hoc analysis of the SCHEDULE trial","volume":"210","author":"Rashidi","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.trre.2021.100655_bb0715","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/TP.0000000000001945","article-title":"Optimizing the safety profile of Everolimus by delayed initiation in De novo heart transplant recipients: results of the prospective randomized study EVERHEART","volume":"102","author":"Potena","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2021.100655_bb0720","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1517\/14740338.2016.1132698","article-title":"Safety of mTOR inhibitors in adult solid organ transplantation","volume":"15","author":"Ventura-Aguiar","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.trre.2021.100655_bb0725","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.thromres.2013.07.004","article-title":"Treatment with everolimus is associated with a procoagulant state","volume":"132","author":"Baas","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.trre.2021.100655_bb0730","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.transproceed.2017.12.003","article-title":"Life-threatening Everolimus-associated pneumonitis: a case report and a review of the literature","volume":"50","author":"Almeida","year":"2018","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2021.100655_bb0735","first-page":"491","article-title":"Late pulmonary toxicity associated with Everolimus in a renal transplant patient and review of the literature","volume":"16","author":"Velioglu","year":"2018","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0740","doi-asserted-by":"crossref","first-page":"305931","DOI":"10.1155\/2014\/305931","article-title":"Interstitial lung disease associated with mTOR inhibitors in solid organ transplant recipients: results from a Large phase III clinical trial program of Everolimus and review of the literature","volume":"2014","author":"Lopez","year":"2014","journal-title":"J Transplant"},{"key":"10.1016\/j.trre.2021.100655_bb0745","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/tri.12275","article-title":"Interstitial pneumonitis caused by everolimus: a case-cohort study in renal transplant recipients","volume":"27","author":"Baas","year":"2014","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2021.100655_bb0750","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.trre.2019.07.001","article-title":"Evidence-based practice: guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients","volume":"33","author":"Pascual","year":"2019","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.trre.2021.100655_bb0755","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2021.100655_bb0760","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1111\/liv.12416","article-title":"Fibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: a randomised study of everolimus vs. calcineurin inhibitors","volume":"34","author":"Villamil","year":"2014","journal-title":"Liver Int"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X21000616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X21000616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T16:08:27Z","timestamp":1760630907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X21000616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":152,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0955470X21000616"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2021.100655","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2021.100655","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100655"}}